KRAS and Miyoshi myopathy: Therefore, we used data collected in the CoMMpass study (N = 699; MM patients with all required data available) that supported our hypothesis as only the combination of 1q21 gain/amp with KRAS mutations (7.6% of patients), but not any of them alone (29.8% and 17.7% with only 1q21 gain/amp or KRAS respectively), resulted in a significantly higher risk of soft tissue plasmacytoma development in univariate analysis (HR = 2.7; p = 0.002) and multivariate Cox analysis (HR = 2.4; p = 0.011) with ISS, LDH level, del(13q), and del(17p) (Supplementary Table 5).